Skip to main
CAI

CAI (CAI) Stock Forecast & Price Target

CAI (CAI) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 45%
Buy 36%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

Caris Life Sciences is well-positioned for future growth and market leadership in the precision medicine industry due to its strong financials and innovative product offerings. The company's expanding payer coverage and advanced pipeline demonstrate its ability to capture a significant share of the growing precision oncology testing market. Additionally, the completion of its IPO and significant investment from leading investors, including those with Wall Street backgrounds, highlights the confidence in the company's management team and its potential for long-term success.

Bears say

Caris Life Sciences is facing challenges to maintain its revenue growth due to its significant increase in the company's CMS rate which could potentially lead to a decrease in demand for its services. Additionally, the company's volume growth in Q1 has been below expectations, indicating a potential slowdown in sales. Furthermore, there are concerns about commercialization risks and potential legal risks in a highly competitive market, as well as the need for significant additional revenue to achieve profitability.

CAI (CAI) has been analyzed by 11 analysts, with a consensus rating of Buy. 45% of analysts recommend a Strong Buy, 36% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of CAI and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About CAI (CAI) Forecast

Analysts have given CAI (CAI) a Buy based on their latest research and market trends.

According to 11 analysts, CAI (CAI) has a Buy consensus rating as of May 12, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $29, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $29, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

CAI (CAI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.